Stock Blog Hub » BDX

(BDX) Becton, Dickinson and Company Hikes Dividend

vitalstocks — Wed, 30 Nov 2011 19:46:55 +0000

Becton, Dickinson and Company (BDX) recently declared a quarterly dividend of 45 cents for each common share, representing a hike of 4 cents, or approximately 10%, from the preceding quarter. The company will make the dividend payment on December 30, 2011, to its shareholders of record, as of December 12, 2011. The new quarterly dividend [...]

(BDX) Becton, Dickinson and Company Hikes Dividend

(MDT) Medical Technology Industry Stock Outlook – November 2011 – Industry Outlook

vitalstocks — Fri, 18 Nov 2011 18:52:43 +0000

The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures, reimbursement pressure and the impact of health care reform continues to weigh on the medical devices industry, [...]

(MDT) Medical Technology Industry Stock Outlook – November 2011 – Industry Outlook

(TGT) Chase Track Records If You Want to Profit

InvestmentU — Mon, 12 Sep 2011 17:18:56 +0000

by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 31, 2011: Issue #1590 Perhaps because I have time on my side, I get excited when the market sells off like it did a few weeks ago. I know that I’ll be able to buy quality stocks at a lower price. That’s especially interesting to income [...]

(TGT) Chase Track Records If You Want to Profit

(MDT) Medical Devices Stock Outlook – Sept. 2011 – Industry Outlook

vitalstocks — Thu, 08 Sep 2011 19:53:43 +0000

June quarter results mostly mirror the preceding quarter as a host of macro headwinds (including price and procedure volume pressures) continued to haunt the MedTech industry and weighed on the performance of the incumbent players. Although a number of these issues are expected to linger over the second-half of 2011, the industry is expected to [...]

(MDT) Medical Devices Stock Outlook – Sept. 2011 – Industry Outlook

(CFN) CareFusion Buying Rowa for $150 Million

vitalstocks — Tue, 12 Jul 2011 16:57:24 +0000

Medical technology company CareFusion Corporation (CFN) recently made a deal to buy German medication storage systems maker Rowa GmbH for roughly $150 million. Rowa, which has customers in 30 countries, specializes in high-speed robotic medication storage and retrieval systems for retail and hospital pharmacies. The company has deployed more than 3,500 automation systems in retail [...]

(CFN) CareFusion Buying Rowa for $150 Million

(BAX) Baxter International Presents Sustainability Report

vitalstocks — Wed, 06 Jul 2011 00:10:10 +0000

Baxter International (BAX) recently presented its 2010 Sustainability Report. This was the 12th straight year in which the company has reported on its economic, social and environmental outcomes. This report highlights the company’s progress toward its sustainability goals and its determination to counter challenges to global sustainability through a number of measures. The initiatives mentioned [...]

(BAX) Baxter International Presents Sustainability Report

(BDX) Unilife Completes Validation Tests

vitalstocks — Fri, 01 Jul 2011 16:39:57 +0000

Retractable syringes maker Unilife Corporation (UNIS) has successfully completed all the required validation tests for its Unifill ready-to-fill (prefilled) syringe, representing the final step in the industrialization process of this unique device. The achievement underscores that the Unifill syringe is fully compliant with all major regulatory requirements and meets the company’s own standards for device [...]

(BDX) Unilife Completes Validation Tests

(BAX) Baxter International Gets Favorable Opinion for Drug

vitalstocks — Wed, 29 Jun 2011 17:04:06 +0000

Baxter International (BAX) recently revealed that the Committee for Medicinal Products for Human Use (“CHMP”) belonging to the European Medicines Agency (“EMA”) has given a favorable opinion for extending the therapeutic indications of Kiovig to encompass a new indication for multifocal motor neuropathy (“MMN”), a debilitating disorder needing life-time therapy. Following acceptance by the European [...]

(BAX) Baxter International Gets Favorable Opinion for Drug

(MDT) Medical Devices Stock Outlook – June 2011 – Industry Outlook

vitalstocks — Thu, 23 Jun 2011 01:09:21 +0000

A host of macro headwinds (including price and procedure volume pressure) which hit the MedTech industry last year continued to haunt the sector during the March quarter and encumber growth. Although a number of these issues are expected to linger through the remainder of 2011, the industry is expected to fare relatively better this year [...]

(MDT) Medical Devices Stock Outlook – June 2011 – Industry Outlook

(BDX) Unilife Hosts White House Business Council Meeting

vitalstocks — Thu, 23 Jun 2011 01:05:21 +0000

Unilife Corporation (UNIS) recently hosted Kathleen Merrigan, Deputy Secretary of the U.S. Department of Agriculture (“USDA”), for a White House Business Council (“WHBC”) meeting with local business chiefs at its plant in York, Pennsylvania. The White House set up the WHBC under the leadership of President Obama. The WHBC is currently holding “The Winning the [...]

(BDX) Unilife Hosts White House Business Council Meeting

(VIVO) FDA OKs Meridian C. Difficile Test

vitalstocks — Fri, 13 May 2011 20:25:43 +0000

Diagnostic test kit maker Meridian Bioscience (VIVO) has clinched the approval of U.S. Food and Drug Administration (“FDA”) for its new C. difficile (Clostridium difficile) test dubbed Premier C. difficile GDH. The approval of this next-generation test broadens the Cincinnati-based company’s portfolio of C. difficile tests and underscores its sustained commitment to bring out breakthrough [...]

(VIVO) FDA OKs Meridian C. Difficile Test

(BDX) Company News for April 27, 2011 – Corporate Summary

vitalstocks — Wed, 27 Apr 2011 17:30:51 +0000

• Hospira (NYSE:HSP) reported Q1 EPS of $0.93, well ahead of the Zacks Consensus Estimate of $0.78 per share. Revenues for the quarter fell less by than a percent to $1.0 billion, topping the Zacks Consensus Estimate of $941.0 million • Ford (NYSE:F) reported Q1 EPS of $0.61, beating the Zacks Consensus Estimate of $0.50 [...]

(BDX) Company News for April 27, 2011 – Corporate Summary

(BAX) Baxter International Launches Fresh Initiative To Mark World Hemophilia Day

vitalstocks — Thu, 14 Apr 2011 22:23:54 +0000

To mark World Hemophilia Day, Baxter International (BAX) recently reiterated its determination to maintain the standard of care and ensure adequate access to treatment for victims of hemophilia and other bleeding disorders. The company is extending its hand to the World Federation of Hemophilia (“WFH”) to start Advocacy in Action, a creative, multi-year project to [...]

(BAX) Baxter International Launches Fresh Initiative To Mark World Hemophilia Day

(COV) Covidien’s Pipeline Device Cleared

vitalstocks — Wed, 13 Apr 2011 16:30:11 +0000

Leading healthcare products maker Covidien plc (COV) has secured Premarket Approval (“PMA”) from the U.S. Food and Drug Administration’s (“FDA”) for its Pipeline Embolization Device for treating adults (22 years and above) with large, giant and wide-neck cerebral aneurysms (a brain vascular disorder). The approval follows the unanimous recommendation of the FDA’s advisory panel in [...]

(COV) Covidien’s Pipeline Device Cleared

(MDT) Medical Devices Industry Outlook – April 2011 – Industry Outlook

vitalstocks — Thu, 31 Mar 2011 23:07:44 +0000

Last year was challenging for medical device companies given the exigent economic conditions and an uncertain healthcare environment. The MedTech industry was hit by several macro headwinds in 2010 including price/volume and utilization pressure and a more restrictive regulatory environment. Although a number of these issues remain, the industry is expected to fare better this [...]

(MDT) Medical Devices Industry Outlook – April 2011 – Industry Outlook

(COV) Covidien plc Quarterly Earnings Top Expectations – Profits Skyrocket

vitalstocks — Fri, 12 Nov 2010 19:46:54 +0000

Ireland-based health care product maker Covidien plc (COV) reported fourth-quarter fiscal 2010 (ended September 24) adjusted earnings per share of 84 cents, exceeding the Zacks Consensus Estimate of 74 cents and the year-ago earnings of 71 cents. For fiscal 2010, adjusted earnings of $3.38 per share outshone the Zacks Consensus Estimate of $3.28 and were [...]

(COV) Covidien plc Quarterly Earnings Top Expectations – Profits Skyrocket

(BDX) Company News for November 4, 2010 – Corporate Summary

vitalstocks — Thu, 04 Nov 2010 17:42:48 +0000

• Qualcomm (NASDAQ:QCOM) posted better-than-expected third-quarter earnings of $0.68, up from estimates of $0.59, and revenues of $2.95 billion, that beat estimates of $2.85 billion • NRG Energy (NYSE:NRG) posted a third quarter earnings and revenue miss, with results of $0.87 below estimates for $$0.89, and revenues of $2.7 billion, off 7.9% YoY shy of estimates for [...]

(BDX) Company News for November 4, 2010 – Corporate Summary

(BAX) Baxter International Introduces GLASSIA

vitalstocks — Wed, 03 Nov 2010 18:20:26 +0000

Medical products giant Baxter International (BAX) officially commenced the U.S. launch of GLASSIA Alpha 1-Proteinase inhibitor for the treatment of emphysema. The company secured exclusive marketing rights to GLASSIA in the U.S., Canada, Australia and New Zealand from Israel-based biopharmaceuticals company Kamada Ltd in August 2010. The distribution deal calls for an upfront cash payment [...]

(BAX) Baxter International Introduces GLASSIA

(COV) Covidien Raises Quarterly Dividend by 11%

vitalstocks — Tue, 12 Oct 2010 14:32:25 +0000

Covidien plc (COV), a leading healthcare products maker, recently enhanced shareholder returns by raising its quarterly dividend by 11% to 20 cents a share from 18 cents. The revised quarterly dividend is payable on Nov 8, 2010, to shareholders of record as on Oct 4, 2010. This represents the Ireland-based company’s second dividend hike over [...]

(COV) Covidien Raises Quarterly Dividend by 11%

(GPRO) Gen-Probe Files Pre-market Approval Application for Prostate Cancer Test

vitalstocks — Mon, 27 Sep 2010 05:04:47 +0000

Diagnostic products maker Gen-Probe Inc. (GPRO) has submitted a Pre-market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its PROGENSA PCA3 assay, a novel molecular test designed to aid the diagnosis of prostate cancer. Gen-Probe is seeking FDA approval to use the assay to test urine specimens from men who earlier [...]

(GPRO) Gen-Probe Files Pre-market Approval Application for Prostate Cancer Test

(COV) Covidien Beats The Street by a Nickel

vitalstocks — Fri, 30 Jul 2010 21:24:20 +0000

Ireland-based healthcare product maker Covidien plc (COV) reported third-quarter fiscal 2010 results with adjusted (excluding one-time items such as restructuring charges and tax-related adjustments) earnings per share of 85 cents beating the Zacks Consensus Estimate of 80 cents and exceeding the year-ago quarter earnings of 74 cents. Net income from continued operation sailed 29% year-over-year [...]

(COV) Covidien Beats The Street by a Nickel

(BAX) Baxter International to Recall Infusion Pumps

vitalstocks — Thu, 15 Jul 2010 15:21:33 +0000

Medical product giant Baxter International Inc. (BAX) has decided to recall all of its Colleague infusion pumps in the U.S. over the next two years. The decision is based on the final order of the U.S. Food and Drug Administration (FDA). Baxter will either offer the Colleague infusion pump owners a no-cost replacement or offer [...]

(BAX) Baxter International to Recall Infusion Pumps

(GPRO) Gen-Probe Invests $50 Million in Pacific Biosciences

vitalstocks — Mon, 05 Jul 2010 16:14:37 +0000

Diagnostic product maker Gen-Probe Inc (GPRO) has made a $50 million strategic investment in privately-held DNA sequencing firm Pacific Biosciences (PacBio). The companies will collaborate on developing products based on their proprietary technologies. Per the deal, the companies will combine their efforts to develop new clinical diagnostic systems, leveraging PacBio’s Single Molecule Real Time (SMRT) [...]

(GPRO) Gen-Probe Invests $50 Million in Pacific Biosciences

(BAX) Baxter International Recalls Products

vitalstocks — Thu, 20 May 2010 00:29:25 +0000

Baxter International Inc. (BAX) has recently initiated a voluntary recall of all lots of its Hylenex recombinant as a result of glass particles found in vials of the product. Hylenex increases the absorption of fluids to boost injected drugs and for fluids and drugs administered under the skin. Baxter licenses the Hylenex recombinant technology from [...]

(BAX) Baxter International Recalls Products

(MDT) Medical Devices Stock Review – May 2010 – Industry Outlook

vitalstocks — Tue, 11 May 2010 21:55:06 +0000

The global medical devices industry is fairly large, with annual worldwide sales in 2009 in excess of $220 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different categories such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices, Healthcare IT, etc. We recommend companies providing life-sustaining products to investors in [...]

(MDT) Medical Devices Stock Review – May 2010 – Industry Outlook

(BAX) Baxter International Analyst Downgrades the Stock

vitalstocks — Wed, 05 May 2010 20:51:18 +0000

We recently downgraded Baxter International Inc. (BAX) to “Underperform” with a target price of $41 based on a P/E of roughly 10.4x our fiscal 2010 EPS estimate of $3.95. The company faces significant product recall issues and has also lowered its sales, earnings per share and cash flow outlook for fiscal 2010. This prompted us [...]

(BAX) Baxter International Analyst Downgrades the Stock

(BDX) Becton, Dickinson and Company Earnings Tops Estimate

vitalstocks — Thu, 29 Apr 2010 14:07:17 +0000

Becton, Dickinson and Company (BDX) reported second quarter fiscal 2010 earnings per share of $1.27, surpassing the Zacks Consensus Estimate of $1.23 and the year-ago earnings of $1.17. Sales Total revenues in the second quarter increased 7.0% year over year to $1.845 billion. Excluding foreign currency translation, total revenues increased 6.6% year over year. Growth [...]

(BDX) Becton, Dickinson and Company Earnings Tops Estimate

(MASI) Masimo Wins New Customer Nassau University Medical Center

vitalstocks — Mon, 19 Apr 2010 01:40:33 +0000

Masimo Corp. (MASI) recently reported that its new customer, Nassau University Medical Center (NUMC), has completed its system-wide conversion to Masimo SET pulse oximetry technology. The conversion allows clinicians to monitor NUMC patients non-invasively using the latest pulse oximetry technology. This in turn provides real time data for vital parameters that aid clinicians in faster [...]

(MASI) Masimo Wins New Customer Nassau University Medical Center

(BAX) Baxter International Posts Encouraging Clinical Study Results

vitalstocks — Wed, 14 Apr 2010 21:11:09 +0000

Baxter International Inc. (BAX) recently produced encouraging results of its 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D (Immune Globulin Intravenous [Human]) for mild-to-moderate Alzheimer’s disease. The clinical trial measures three key parameters: cognitive, functional and neuroimaging. All these parameters produced positive data. The Phase II clinical study enrolled 24 patients in [...]

(BAX) Baxter International Posts Encouraging Clinical Study Results

(BAX) Baxter International Receives FDA Approval for TachoSil

vitalstocks — Wed, 07 Apr 2010 22:59:19 +0000

Baxter International Inc. (BAX) and Nycomed recently received the U.S. Food and Drug Administration (FDA) approval of TachoSil, an absorbable fibrin sealant patch that can be used in addition to hemostasis to stop bleeding during cardiovascular surgeries. Baxter expects to launch the product in the U.S. in the second half of 2010. TachoSil is the [...]

(BAX) Baxter International Receives FDA Approval for TachoSil

(MASI) Masimo Analysts Maintain Neutral Rating

vitalstocks — Wed, 17 Mar 2010 19:33:16 +0000

We continue to maintain our ‘Neutral’ rating on Masimo Corp. (MASI) with a target price of $28 based on a P/E of 28.0x our fiscal 2010 EPS estimate of $1. The company’s fourth quarter fiscal 2009 results reflect a mixed trend. Masimo reported fourth-quarter earnings per share of 23 cents, surpassing the Zacks Consensus Estimate [...]

(MASI) Masimo Analysts Maintain Neutral Rating

(BDX) Becton, Dickinson and Company Recalls Catheters

vitalstocks — Wed, 10 Feb 2010 20:52:16 +0000

Becton, Dickinson and Company (BDX) recently started expanding the recall of its catheters as a result of a manufacturing problem that could cause fatal embolisms or blood leakage. Becton is recalling its defective Q-Syte Luer Access Devices and Nexiva Closed IV Catheter Systems. The company started the initial recall of these products on Oct 28, [...]

(BDX) Becton, Dickinson and Company Recalls Catheters

(BAX) Baxter International Downgraded to Neutral

vitalstocks — Sat, 06 Feb 2010 00:24:50 +0000

We recently downgraded Baxter International Inc. (BAX) to Neutral. The stock was assigned a target price of $59 based on an approximate P/E multiple of 13.9x our fiscal 2010 earnings estimate of $4.25. Baxter recently reported fourth quarter and fiscal 2009 results. For the fourth quarter, earnings per share were $1.03, in line with the [...]

(BAX) Baxter International Downgraded to Neutral

(BDX) Becton, Dickinson and Company Beats Expectations – Bumps Estimates

vitalstocks — Tue, 02 Feb 2010 18:26:27 +0000

We recently reiterated our Neutral rating on Becton, Dickinson and Company (BDX) with a target price of $78 based on a P/E of approximately 15.3x our fiscal 2010 EPS estimate of $5.10. Becton recently reported first quarter fiscal 2010 results. Earnings per share of $1.30 easily beats the Zacks Consensus Estimate of $1.20 and the [...]

(BDX) Becton, Dickinson and Company Beats Expectations – Bumps Estimates

(MDRX) Medical Devices Stock Review – Feburary 2010 – Industry Outlook

vitalstocks — Mon, 01 Feb 2010 22:23:50 +0000

The global medical devices industry is fairly large, with annual worldwide sales in excess of $200 billion. The U.S. accounts for approximately 41% of this market. The industry is divided into different categories such as Cardiology, Oncology, Neuro, Orthopedic, Aesthetic Devices, Healthcare IT, etc. We recommend companies providing life-sustaining products to investors in the medical [...]

(MDRX) Medical Devices Stock Review – Feburary 2010 – Industry Outlook

(BDX) Becton Dickinson and Company Surpasses Consensus Estimates

vitalstocks — Thu, 28 Jan 2010 20:28:04 +0000

Becton, Dickinson and Company (BDX) reported first quarter fiscal 2010 earnings per share of $1.30, surpassing the Zacks Consensus Estimate of $1.20 and the year-ago earnings of $1.25. Total Revenues Total revenues in the first quarter increased 12% year over year to $1.917 billion. Excluding the foreign currency translation (FX), total revenues increased 9% year [...]

(BDX) Becton Dickinson and Company Surpasses Consensus Estimates

(BAX) Baxter International Reports Earnings In-Line

vitalstocks — Thu, 28 Jan 2010 20:22:58 +0000

Baxter International Inc. (BAX) reported financial results for the fourth quarter and full fiscal 2009. For the fourth quarter, earnings per share were $1.03, in line with the Zacks Consensus Estimate and higher than the year-ago earnings of 91 cents. For full fiscal 2009, earnings per share were $3.80, again in line with the Zacks [...]

(BAX) Baxter International Reports Earnings In-Line

(MASI) Masimo Corporation Announces Positive Results From Clinical Study

vitalstocks — Mon, 25 Jan 2010 20:30:54 +0000

Masimo Corporation (MASI) recently announced positive results form its 21-month clinical study on the impact of the Masimo Patient SafetyNet remote monitoring and clinician notification system. Results indicated that continuous pulse oximetry monitoring and clinician notification in post-surgical patients on the general floor leads to a significant drop in key clinical outcome measures, such as [...]

(MASI) Masimo Corporation Announces Positive Results From Clinical Study

(MASI) Masimo Corporation Can Now Earn While Patients Test Device Effectiveness

vitalstocks — Tue, 05 Jan 2010 18:29:56 +0000

Masimo Corporation (MASI) has recently received a new Current Procedural Terminology (CPT) code from the American Medical Association, 88738, for its noninvasive hemoglobin (SpHb) measurement. Medicare has priced the new CPT code at $7.19 on its 2010 Medicare Clinical Laboratory Fee Schedule. The new pricing has been effective since Jan 1, 2010. The new CPT [...]

(MASI) Masimo Corporation Can Now Earn While Patients Test Device Effectiveness

(MASI) Masimo Corporation in Expansion Mode

vitalstocks — Wed, 30 Dec 2009 01:04:32 +0000

Masimo Corp. (MASI) recently announced the expansion of its corporate campus in Irvine, California with the addition of an adjacent 32,000 sq. ft. building. This is the company’s third building on its corporate campus. Masimo stated that the new building is expected to accommodate more than 200 employees. The expansion of Masimo’s corporate headquarters will further [...]

(MASI) Masimo Corporation in Expansion Mode

(MASI) Masimo Completes Conversion of New Customer

vitalstocks — Tue, 15 Dec 2009 01:30:13 +0000

Masimo Corp. (MASI) reported that its new customer, Brookdale University Hospital and Medical Center in Brooklyn, New York, has completed its system-wide conversion to Masimo SET pulse oximetry technology. Brookdale has also installed Masimo’s first-ever continuous and noninvasive hemoglobin monitoring (SpHb) technology in its select care settings. This allows clinicians to detect and treat chronic [...]

(MASI) Masimo Completes Conversion of New Customer

(BDX) Becton, Dickinson and Co Receives FDA Clearance

vitalstocks — Wed, 09 Dec 2009 23:23:44 +0000

Becton, Dickinson and Co. (BDX) recently announced that BD Diagnostics, a segment of BDX, has received U.S. Food and Drug Administration (FDA) clearance to utilize its BD ProbeTec Chlamydia trachomatis (CT) Qx and BD ProbeTec Neisseria gonorrhoeae (GC) Qx Amplified DNA Assays with samples collected from women’s routine liquid-based Pap testing for cervical cancer screening. [...]

(BDX) Becton, Dickinson and Co Receives FDA Clearance

(BAX) Baxter International Gets H1N1 Vaccine Order

vitalstocks — Sat, 05 Dec 2009 01:10:34 +0000

Baxter International Inc. (BAX) recently received another order for 10,000 H1N1 vaccines, commonly known as “swine flu,” from Slovenia. The order is worth $158,700 (105,000 euros). It is estimated that the number of vaccines ordered is sufficient to cover 5,000 people in the country. Slovenia has also decided to purchase a total of 1.3 million [...]

(BAX) Baxter International Gets H1N1 Vaccine Order

(MASI) Masimo Corporation Earns FDA New Product Approval

vitalstocks — Wed, 02 Dec 2009 22:21:48 +0000

Masimo Corporation (MASI) recently received the U.S. Food and Drug Administration (FDA) approval for its new product, Masimo Rainbow SET Acoustic Monitoring. The new product enables noninvasive and continuous monitoring of human respiration rate (RRa). The data provided is accurate, easy-to-use, and thereby enhances patient compliance. With the approval, Masimo expects to launch the product [...]

(MASI) Masimo Corporation Earns FDA New Product Approval

(MASI) Masimo Corporation Renews Deal with Advocate Health Care

vitalstocks — Mon, 30 Nov 2009 04:25:19 +0000

Masimo Corporation (MASI) announced that one of its prominent customers, Advocate Health Care, has recently renewed its multi-year, system-wide contract for Masimo SET pulse oximetry technology. Advocate Health Care is Illinois’ largest and one of the top ten health care providers in the U.S. It has more than 200 patient-care sites across Chicago. Financial terms [...]

(MASI) Masimo Corporation Renews Deal with Advocate Health Care

(BDX) Becton, Dickinson and Company Acquires HandyLab

vitalstocks — Mon, 23 Nov 2009 16:34:12 +0000

Becton, Dickinson and Company (BDX) recently completed the acquisition of HandyLab, Inc, an Ann Arbor, Michigan-based company that develops and manufactures automation platforms and molecular diagnostic assays. The transaction costs Becton $275 million. The acquisition enables Becton to develop and commercialize its BD GeneOhm molecular assays on the HandyLab Jaguar platform, the first fully integrated [...]

(BDX) Becton, Dickinson and Company Acquires HandyLab

(CFN) CareFusion Corporation Enters Agreement with Masimo

vitalstocks — Sat, 14 Nov 2009 22:12:01 +0000

CareFusion Corp. (CFN) entered into a multi-year technology licensing agreement with Masimo Corp. (MASI) regarding the use of Masimo Rainbow SET Pulse CO-Oximetry technology in CareFusion infusion and respiratory products, which are presently under development. The agreement enables CareFusion’s future infusion and respiratory products to non-invasively and continuously measure multiple blood constituents to more accurately [...]

(CFN) CareFusion Corporation Enters Agreement with Masimo

(BDX) Becton, Dickinson and Co Reports Strong Results

vitalstocks — Mon, 09 Nov 2009 03:21:04 +0000

Becton, Dickinson and Co. (BDX) reported strong fourth quarter and full fiscal 2009 results. For the fourth quarter, earnings per share were $1.25, beating the Zacks Consensus Estimate by a cent and the year-ago earnings by 14 cents. For fiscal 2009, earnings per share came in at $4.95, which was below the Zacks Consensus Estimate [...]

(BDX) Becton, Dickinson and Co Reports Strong Results

(BDX) Becton-Dickinson and Company Set for Acquisition of HandyLab

vitalstocks — Wed, 28 Oct 2009 03:16:20 +0000

Becton-Dickinson and Company (BDX) is set to acquire HandyLab Inc., an Ann Arbor, Michigan-based company that develops and manufactures automation platforms and molecular diagnostic assays. The acquisition is expected to close by the year end. Financial terms of the deal have not been disclosed. Becton had already entered into a development and distribution agreement with [...]

(BDX) Becton-Dickinson and Company Set for Acquisition of HandyLab

(BAX) Baxter International Eyes Swine Flu Market

vitalstocks — Tue, 20 Oct 2009 20:13:28 +0000

Baxter International Inc. (BAX) announced that it sees multiyear opportunity in H1N1 vaccines, commonly known as Swine Flu vaccines. The company expects to recognize $30 million to $40 million in revenues from swine flu vaccines in the fourth quarter. Baxter has not speculated on H1N1 vaccine sales beyond the fourth quarter. However Incorporatedreasing demand has [...]

(BAX) Baxter International Eyes Swine Flu Market